## AUP1
- **UniProt:** Q9Y679 · **batch:** proteostasis-batch-2026-06-06 · **review status:** COMPLETE (thorough; 40 annotations reviewed)
- **PN placement:** `ER proteostasis|...|ER associated degradation|Retrotranslocation channel complex`; `ALP|...|Lipophagy|Ubiquitination of lipid droplet surface proteins`; `UPS|Ubiquitin and UBL binding|protein quality control|ERAD cofactor|CUE`. PN-node mappings: ERAD group=mapped/exact GO:0036503; Lipophagy type=mapped/propagation GO:0061724; ERAD-cofactor type=mapped/propagation GO:0097466; broader ancestors=no_mapping or context_only.
- **Consistency:** Strong agreement across all sources. Deep research (falcon), review YAML, and PN annotations all converge on AUP1 as an ER/lipid-droplet monotopic membrane adaptor that recruits the E2 UBE2G2 (via G2BR) and binds ubiquitin (CUE) to drive ERAD, with secondary LD-clustering and (virus-induced) lipophagy roles. No contradictions. The three PN branch rows (ER/ALP/UPS) each map to a function the review independently accepts as core (ERAD, ubiquitin binding/E2 recruitment) or non-core (lipophagy).
- **PN story / NEW pressure:** No NEW GO pressure. All three projected terms are already captured. GO:0036503 ERAD pathway and GO:0061724 lipophagy are present in GOA and ACCEPT/KEEP_AS_NON_CORE in the review (lipophagy correctly flagged virus-context, non-core). GO:0097466 ubiquitin-dependent glycoprotein ERAD pathway (verified real) is NOT in GOA and is more specific; the review does not list it but its parent GO:0036503 is accepted. Review's `proposed_new_terms` is empty — appropriate.
- **Mapping strategy:** No change warranted. ERAD group=mapped/exact is well justified (AUP1 is a bona fide ERAD factor). The two propagation-scope mappings (lipophagy, glycoprotein-ERAD) are defensible at gene level for AUP1; the no_mapping/context_only calls on broad UPS/ALP ancestors are consistent with the TOMM20/HSPA8 "too broad" precedent.
- **Evidence alignment:** PN row 2 cites Spandl 2011 (PMID:21127063), which is in the review (G2BR/Ube2g2 binding). PN otherwise cites few papers; the review is far richer (Klemm 2011 PMID:21857022, Jo 2013 PMID:23223569, Smith 2021 PMID:34879065, Frachon 2024 PMID:38474353, flavivirus PMID:29902443). No divergence — review is a strict superset.
- **Verdict:** Consistent and well-curated; no NEW term, no mapping change. Optional: GO:0097466 could be added to the review as a more-specific ERAD term but is not required.